Literature DB >> 30499141

Relating optical coherence tomography to visual fields in glaucoma: structure-function mapping, limitations and future applications.

Jonathan Denniss1, Andrew Turpin2, Allison M McKendrick3.   

Abstract

Combining information from optical coherence tomography (OCT) imaging and visual field testing is useful in the clinical assessment and monitoring of patients with glaucoma. Measurements of retinal nerve fibre layer thickness or neuroretinal rim width taken around the optic nerve head may be related to the visual field using a structure-function map. In this review, the structure-function mapping methods in clinical use are discussed. Typical clinical maps provide a population average, 'one size fits all' representation, but in recent years methods for customising structure-function maps to individual eyes have been developed and these are reviewed here. In the macula, visual field stimuli stimulate photoreceptors for which associated retinal ganglion cells are peripherally displaced. Recently developed methods that relate OCT measurements to visual field test locations in the macula are therefore also reviewed. The use of structure-function maps to relate OCT measurements to localised visual field sensitivity in new applications is also explored. These new applications include the selection of visual field test locations and stimulus intensities based on OCT data, and the formal post-test combination of results across modalities. Such applications promise to exploit the structure-function relationship in glaucoma to improve disease diagnosis and monitoring of progression. Limitations in the validation and use of current structure-function mapping techniques are discussed.
© 2018 Optometry Australia.

Entities:  

Keywords:  glaucoma; optical coherence tomography; perimetry; visual fields

Mesh:

Year:  2018        PMID: 30499141     DOI: 10.1111/cxo.12844

Source DB:  PubMed          Journal:  Clin Exp Optom        ISSN: 0816-4622            Impact factor:   2.742


  7 in total

Review 1.  Macular imaging with optical coherence tomography in glaucoma.

Authors:  Vahid Mohammadzadeh; Nima Fatehi; Adeleh Yarmohammadi; Ji Woong Lee; Farideh Sharifipour; Ramin Daneshvar; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Surv Ophthalmol       Date:  2020-03-19       Impact factor: 6.048

2.  Longitudinal Macular Structure-Function Relationships in Glaucoma.

Authors:  Vahid Mohammadzadeh; Alessandro Rabiolo; Qiang Fu; Esteban Morales; Anne L Coleman; Simon K Law; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Ophthalmology       Date:  2020-01-22       Impact factor: 12.079

3.  Repeatability of quantitative measurements of retinal layers with SD-OCT and agreement between vertical and horizontal scan protocols in healthy eyes.

Authors:  Alberto Domínguez-Vicent; Rune Brautaset; Abinaya Priya Venkataraman
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

4.  Improving Personalized Structure to Function Mapping From Optic Nerve Head to Visual Field.

Authors:  Andrew Turpin; Allison M McKendrick
Journal:  Transl Vis Sci Technol       Date:  2021-01-08       Impact factor: 3.283

5.  Correlation Between Optical Coherence Tomography and Photopic Negative Response of Flash Electroretinography in Ganglion Cell Complex Assessment in Glaucoma Patients.

Authors:  Mohammad Hasan Awwad; Ossama Nada; Momen Mahmoud Hamdi; Amany Abd El-Fattah El-Shazly; Sheriff Elwan
Journal:  Clin Ophthalmol       Date:  2022-03-23

6.  Prediction of visual field defects from macular optical coherence tomography in glaucoma using cluster analysis.

Authors:  Janelle Tong; David Alonso-Caneiro; Michael Kalloniatis; Barbara Zangerl
Journal:  Ophthalmic Physiol Opt       Date:  2022-05-22       Impact factor: 3.992

7.  Custom extraction of macular ganglion cell-inner plexiform layer thickness more precisely co-localizes structural measurements with visual fields test grids.

Authors:  Janelle Tong; David Alonso-Caneiro; Nayuta Yoshioka; Michael Kalloniatis; Barbara Zangerl
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.